<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:hpo ids='HP_0009733'>Glioma</z:hpo> and <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya syndrome</z:e> are both potential complications of <z:hpo ids='HP_0001067'>neurofibromatosis</z:hpo> type 1 (NF1) </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we report the first case of NF1 concomitantly presenting with <z:hpo ids='HP_0100843'>glioblastoma</z:hpo> 10 years after surgical treatment of <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>CASE REPORT: A 14-year-old boy with NF1 was incidentally diagnosed by magnetic resonance imaging (MRI) with a <z:e sem="disease" ids="C1336733" disease_type="Neoplastic Process" abbrv="">thalamic tumor</z:e> during a follow-up for <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya syndrome</z:e>, which had been treated with surgery 10 years earlier </plain></SENT>
<SENT sid="3" pm="."><plain>After observation for 36 months, he developed left <z:hpo ids='HP_0001269'>hemiparesis</z:hpo>, and MRI revealed an increase in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size and obstructive <z:hpo ids='HP_0000238'>hydrocephalus</z:hpo> due to the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Needle biopsy was performed through small craniotomy, and the histological diagnosis was <z:hpo ids='HP_0100843'>glioblastoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>After concurrent chemoradiotherapy with 23 cycles of temozolomide, partial response of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> was observed </plain></SENT>
<SENT sid="6" pm="."><plain>However, 24 months after the start of the initial therapy, the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> showed regrowth, and the patient died 30 months after the initial therapy </plain></SENT>
<SENT sid="7" pm="."><plain>No cerebrovascular events associated with <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya syndrome</z:e> and chemoradiotherapy were observed during the clinical course of <z:hpo ids='HP_0100843'>glioblastoma</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>DISCUSSION: <z:hpo ids='HP_0100843'>Glioblastoma</z:hpo> is a fatal disease in children, and our patient successfully received chemoradiotherapy with temozolomide despite the diagnoses of NF1 and <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya syndrome</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Although radiotherapy or chemotherapy potentially causes cerebrovascular complications, chemoradiotherapy might be feasible for <z:hpo ids='HP_0100843'>glioblastoma</z:hpo> treatment in patients with <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya syndrome</z:e> and NF1 </plain></SENT>
<SENT sid="10" pm="."><plain>The following issues are discussed in the management of the present case: the indication of biopsy in NF1 cases, the method of surgery, and the treatment protocol for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> concomitant with <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya disease</z:e> or syndrome </plain></SENT>
</text></document>